Stone disease

Presented by Margaret S. Pearle, MD, University of Texas SouthwesternMedical Center, Dallas.

Related Content:

Drug Therapy

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

FDA approves androgen inhibitor for metastatic PCa